BDX

Business profile & competitive position

Becton, Dickinson and Company is classified in the Healthcare sector, specifically the Medical - Instruments & Supplies industry. As of its most recent 10-K, BD develops, manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical companies and the general public. Its customer solutions target medication management, patient safety, infection prevention, surgical and interventional procedures, drug delivery, anesthesiology, infectious disease and cancer diagnostics, and cellular research. As of September 30, 2025, the company operated through three worldwide segments: BD Medical, BD Life Sciences and BD Interventional.

The competitive narrative implied by the current numbers is more about scale and diversification than about outsized pricing power. BD carries a market capitalization of $52.6 billion, but its net margin is 4.5% and its return on equity is 3.8%. Those figures are modest for a company of this size. A low single-digit ROE and a thin net margin do not, on their own, point to a deep economic moat generated by premium pricing. Instead, they suggest a business that derives durability from a wide product portfolio, long-standing customer relationships and high switching costs in clinical settings, while currently operating with compressed profitability. The beta of 0.26 indicates the stock has moved far less than the overall market, consistent with a defensive, large-cap healthcare name rather than a high-growth disrupter.

Financial posture

At a share price of $190.74, BD commands a market cap of $52.6 billion and trades at a price-to-earnings ratio of 57.5. That multiple is high relative to the company’s current profitability: net margin is only 4.5% and ROE is 3.8%. The gap between the valuation multiple and the trailing returns underscores that investors are either looking through near-term earnings weakness or are pricing in benefits from the recently reorganized structure and pending corporate transactions.

On the technical side, the current RSI is 75.5 and the 50-day exponential moving average is $167.50. The stock is therefore well above its medium-term average and in technically overbought territory. The beta of 0.26 remains the defining macro characteristic: BD is likely to underreact to broad market swings, which is typical for a large, diversified medical-supplies business. No price target or investment recommendation is implied by these observations; they simply describe a stock that looks expensive on trailing earnings and stretched on momentum but defensive on market sensitivity.

Strategic priorities & outlook

BD’s most recent 10-K outlines a business in the middle of structural change. Effective October 1, 2025, the company reorganized into five separately managed segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences. This replaces the prior three-segment structure of BD Medical, BD Life Sciences and BD Interventional.

The most significant pending transaction is the Reverse Morris Trust combination of BD’s Biosciences and Diagnostic Solutions business with Waters Corporation, expected to close around the end of the first quarter of calendar year 2026. BD expects to receive approximately $4 billion in cash and its shareholders to own roughly 39.2% of the combined company after the deal. On the acquisition side, BD completed the $3.914 billion purchase of Edwards Lifesciences’ Critical Care product group in September 2024, integrating it as BD Advanced Patient Monitoring within BD Medical.

Other notable transactions include the April 2022 divestiture of the Diabetes Care business into Embecta Corp. and the August 2023 sale of the Interventional segment’s Surgical Instrumentation platform, which produced a pre-tax gain of approximately $268 million. Operationally, BD has manufacturing in 18 countries outside the United States across EMEA, Greater Asia, Latin America and Canada, which exposes the company to foreign economic conditions and exchange-rate swings. The filing notes that foreign profitability has fluctuated more than U.S. profitability and that some non-U.S. activities carry greater risk.

Macro & geopolitical exposure

Because BD sits in the Medical - Instruments & Supplies industry, its macro profile is shaped by healthcare regulation, reimbursement policy, trade rules and global supply chains. Medical-device makers face FDA oversight, quality-system requirements and the risk of product recalls or consent decrees. Tariffs or trade barriers on plastics, electronic components and sterilization-related materials can affect input costs. Government and private reimbursement rates influence hospital purchasing, which in turn affects demand for BD’s devices and consumables. Currency risk is elevated here because the company manufactures in 18 countries and books revenue in multiple currencies; a stronger U.S. dollar can reduce the translated value of foreign sales, while a weaker dollar can raise costs for imported components. Demographic tailwinds such as an aging population support long-run demand for infection prevention, surgical products and diagnostics, but that demand is delivered through a regulated, price-sensitive procurement channel.

Recent developments

The most recent news flow has been event-driven rather than transformational. On August 20, 2026, Zacks reported that BDX completed enrollment in the PREVENT trial for its Phasix Mesh study. On August 17, 2026, a PR Newswire release said BD appointed Gary Sorsher as Chief Quality Officer while Jeff Silvestri is set to retire. Leadership transitions in the quality function are worth tracking for a device manufacturer with global manufacturing and regulatory obligations.

August 13, 2026 brought two headlines: Zacks included BDX in a discussion of “Dividend Kings” alongside ED, EMR and PH after earnings, while Seeking Alpha highlighted Becton Dickinson’s “earnings beat again” and credited the diverse clinical portfolio for continued growth. These items align with the earnings pattern described below: consistent bottom-line beats across a broad product base.

Earnings behavior & post-earnings drift

BDX has delivered an earnings beat in each of the last eight reported quarters, for a beat rate of 8 out of 8, or 100%. The average earnings surprise across that stretch is 8.2%. More importantly for traders, the average 5-day price move in the five trading days following earnings is +3.66%, classified as an “up” post-earnings drift.

The most recent four quarters show that the immediate next-day reaction can diverge from the subsequent five-day drift. On August 6, 2026, BD reported EPS of $3.23 against an estimate of $3.14, a 2.9% beat; the stock slipped 0.12% the next day but rose 2.77% over the following five sessions. On May 7, 2026, EPS came in at $2.90 versus $2.78, a 4.3% surprise; the stock fell 2.5% the next day and declined 5.74% over the next five days, a rare negative drift. On February 9, 2026, EPS of $2.91 crushed the $2.21 estimate by 31.7%, driving a 5.3% next-day gain and an 8.8% five-day gain. On November 6, 2025, EPS of $3.96 edged the $3.92 estimate by 1.0%, with a 0.25% next-day move and an 8.82% five-day advance.

The next scheduled report is November 5, 2026, before the market opens, with a consensus EPS estimate of $4.06. The recent track record suggests the market has tended to reward BD beats over a multi-day window, even when the first-day reaction is muted or negative, but the May 2026 quarter shows that a post-earnings decline is possible even after a beat.

For a deeper dive into how institutional analysts are interpreting BD’s valuation, restructuring and earnings setup, readers should review the full institutional verdict on the ticker page.